Concarlo Therapeutics

Concarlo Therapeutics is pioneering a transformative approach to drug-resistant cancers by directly targeting the p27 protein, a master regulator of cell proliferation. Founded by Dr. Stacy Blain, a world expert in p27 biology, the company leverages a deep understanding of the cell cycle to develop therapies that inhibit both CDK4/6-driven proliferation and CDK2-driven resistance. With a seasoned leadership team and a clear focus on high-unmet-need oncology indications, Concarlo is positioned to address a critical gap in precision oncology where resistance remains a major challenge.

A platform targeting the p27 protein to act as a molecular glue, stabilizing inactive p27-cyclin-CDK complexes and inhibiting phosphorylation at Tyr88, thereby indirectly inhibiting CDK4/6 and CDK2 to kill drug-resistant cancer cells.

Total raised: $24M

Competes in the cell cycle inhibitor space against developers of CDK2-selective and dual CDK2/4/6 inhibitors (e.g., AstraZeneca, Pfizer). Concarlo differentiates by directly targeting the upstream regulator p27 (a novel target) with the goal of achieving cytotoxic, not just cytostatic, effects and overcoming multiple resistance pathways.